After the announcement this week that Afrezza, the inhaled insulin treatment for diabetes, is finally available in the U.S. market, stock prices rose for shares of MannKind, the biopharmaceutical company based in Valencia.
Afrezza was approved by the FDA to control high blood sugar in adults with type one and type two diabetes.
But stocks rode the wave of investor optimism and fear in the past year as the Food and Drug Administration delayed approval of the biomed firm’s creation until late June in 2014.
In the past year, stocks hit a low of $4.02 per share on April 1, 2014. Stocks more than doubled, rising to $10.96 per share on June 30 after the FDA approval was announced.
Throughout the rest of the year, investors seemed to anxiously buy and sell while they waited for the company’s plan to unfold.
Later in the summer a distribution agreement was made public between MannKind and Paris-based Sanofi.
While market watchers waited for the first release of Afrezza in the U.S., shares settled in at $5.10 by Dec. 16, 2014.
After this week’s announcement, shares rose again closing at $6.97 at the close of trading on Friday.
